Member Info for PippiLongStockin

Actually, never really liked the muppets myself

Touk and Thorn are like Waldorf and Statler in the cheap seats

Thorno-whatsit please give it a rest. I come on this board infrequently but to try and gauge a bit about current state of play. Your constant drivel once again is a large constituent of what’s on offer. Go invest your time somewhere more productive

This process looks tempting

Who is this Thornogson --- are you also going to tell us that its not a sunny day outside, terrible weather?

Agree but it trains retail investors into when they will receive updates, so there isn’t an expectation for every 2 weeks

Let’s hope so —- and with a strategic investor would be perfect. Unless they hit Nasdaq at that point

They look to be executing to plan.

Clear strategy and now further along it

Confirmed bowl on Avacta —- suggesting recent sell off is over and ready for a run up

https://substack.com/home/post/p-154189444?utm_campaign=post&utm_medium=web

Does anyone know if any shorts have been reducing?

The cash advantages to new sites with landlord contributions etc means the cash on cash returns will fuel the next leg of growth. Provided the festive season has delivered then good chance of an upside in the next trading update.

Wyn, glad you admit that its FUD.

That sounds like progress

And thing is he’s not doing this for avacta, he’s doing it for his profile to pull in the babes

Except it’s not virgilo’s first rodeo on this podcast, he did another one 2 years ago on a different topic

Maybe see an uptick of USA retail investors?

Can they buy AIM stocks?

Particularly love this bit…..

The problem is that cancer is always a mixture of cells, so some cancer cells may have the target antigens and some other cancer cells may not have the target antigens. Your nuclear bomb will go only to the cells with the special marker antigens, but not into the other cells, and some cells may be resistant to this medication and may survive and later on the cancer may reappear. But with this special Avacta technology we target the cancer environment rather than the cancer cells, which means that even if you have differing cancer cells the medication goes into the cancer environment and kills all the cells independently of the type of antigen that they have. This means we may now target all the cancer tissues instead of selected cells with Doxorubicin, which is not a new drug

Interesting the article is not in a medical journal but a ‘thought leadership’ series

Wow new standard of treatment

Interesting isn't it, drawn out for a reason

They need to make sure everything they do now is going to meet FDA expectations. that will add a level of engagement